(NYSEMKT: PLX) Protalix Biotherapeutics's forecast annual revenue growth rate of -4.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.94%.
Protalix Biotherapeutics's revenue in 2026 is $80,619,000.On average, 3 Wall Street analysts forecast PLX's revenue for 2026 to be $6,685,834,853, with the lowest PLX revenue forecast at $6,442,025,064, and the highest PLX revenue forecast at $6,999,097,397. On average, 3 Wall Street analysts forecast PLX's revenue for 2027 to be $5,618,582,883, with the lowest PLX revenue forecast at $4,894,485,537, and the highest PLX revenue forecast at $6,438,077,054.
In 2027, PLX is forecast to generate $5,409,982,902 in revenue, with the lowest revenue forecast at $4,759,528,036 and the highest revenue forecast at $6,148,905,431.